Moderna (MRNA) Other Non-Current Liabilities (2017 - 2026)

Moderna (MRNA) has 10 years of Other Non-Current Liabilities data on file, last reported at $283.0 million in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 3.28% year-over-year to $283.0 million in Q1 2026; TTM through Mar 2026 was $283.0 million, a 3.28% increase from a year earlier, with the FY2025 full-year figure at $285.0 million, up 6.74% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $283.0 million, down from $285.0 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for MRNA reached as high as $285.0 million in Q4 2025 and fell as low as $81.0 million in Q3 2022.
• Historically, Other Non-Current Liabilities has averaged $214.9 million across 5 years, with a median of $262.0 million in 2024.
• Across the five-year window, Other Non-Current Liabilities surged 11200.0% in 2022 and gained 1.81% in 2025, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $135.0 million in 2022, then jumped by 89.63% to $256.0 million in 2023, then climbed by 4.3% to $267.0 million in 2024, then advanced by 6.74% to $285.0 million in 2025, then decreased by 0.7% to $283.0 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $283.0 million in Q1 2026, $285.0 million in Q4 2025, and $281.0 million in Q3 2025.